CN110092830B - 用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体 - Google Patents

用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体 Download PDF

Info

Publication number
CN110092830B
CN110092830B CN201910291444.8A CN201910291444A CN110092830B CN 110092830 B CN110092830 B CN 110092830B CN 201910291444 A CN201910291444 A CN 201910291444A CN 110092830 B CN110092830 B CN 110092830B
Authority
CN
China
Prior art keywords
lam
antibody
seq
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910291444.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110092830A (zh
Inventor
A·平特
A·超德瑞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Priority to CN201910291444.8A priority Critical patent/CN110092830B/zh
Publication of CN110092830A publication Critical patent/CN110092830A/zh
Application granted granted Critical
Publication of CN110092830B publication Critical patent/CN110092830B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/44—Multiple drug resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
CN201910291444.8A 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体 Active CN110092830B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910291444.8A CN110092830B (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662293406P 2016-02-10 2016-02-10
US62/293,406 2016-02-10
PCT/US2017/016058 WO2017139153A1 (en) 2016-02-10 2017-02-01 Novel anti-lam and anti-pim6/lam monoclonal antibodies for diagnosis and treatment of mycobacterium tuberculosis infections
CN201910291444.8A CN110092830B (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体
CN201780017369.5A CN109073649A (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的新颖抗lam和抗pim6/lam单克隆抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780017369.5A Division CN109073649A (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的新颖抗lam和抗pim6/lam单克隆抗体

Publications (2)

Publication Number Publication Date
CN110092830A CN110092830A (zh) 2019-08-06
CN110092830B true CN110092830B (zh) 2023-07-04

Family

ID=59563993

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910291444.8A Active CN110092830B (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体
CN201780017369.5A Pending CN109073649A (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的新颖抗lam和抗pim6/lam单克隆抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780017369.5A Pending CN109073649A (zh) 2016-02-10 2017-02-01 用于诊断和治疗结核分枝杆菌感染的新颖抗lam和抗pim6/lam单克隆抗体

Country Status (10)

Country Link
US (4) US10729771B2 (https=)
EP (2) EP3414573B1 (https=)
JP (4) JP2019506412A (https=)
CN (2) CN110092830B (https=)
AU (2) AU2017218415B2 (https=)
CA (1) CA3013904C (https=)
ES (1) ES2970828T3 (https=)
RU (1) RU2732502C2 (https=)
WO (1) WO2017139153A1 (https=)
ZA (3) ZA201805990B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2970828T3 (es) 2016-02-10 2024-05-30 Univ Rutgers Nuevos anticuerpos anti-lam
US10830760B2 (en) * 2017-12-20 2020-11-10 General Electric Company Device for rapid detection of tuberculosis-lipoarabinomannan (TB-LAM) with enhanced sensitivity
JP2021521462A (ja) * 2018-03-29 2021-08-26 ファウンデーション オブ イノベーティブ ニュー ダイアグノスティクス 抗体または抗体の組み合わせおよび対象の尿試料中のマイコバクテリウム関連抗原の検出のためのその使用
WO2020018806A1 (en) 2018-07-19 2020-01-23 Rutgers, The State University Of New Jersey Methods for dual detection and differentiation of infection by mycobactierum tuberculosis complex and nontuberculous mycobacteria
JP7130045B2 (ja) * 2018-08-31 2022-09-02 富士フイルム株式会社 イムノクロマトグラフキットおよび結核菌の検出方法
CN114341639A (zh) 2019-09-30 2022-04-12 富士胶片株式会社 免疫检查方法及浓缩用夹具
JP7274595B2 (ja) 2019-09-30 2023-05-16 富士フイルム株式会社 イムノクロマトグラフィー
CN111337665A (zh) * 2020-01-16 2020-06-26 卢氏实验室公司 一种用于检测肺结核感染的免疫层析试纸条及其制备方法
WO2021152966A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 イムノクロマトグラフィー
JP7350100B2 (ja) 2020-01-31 2023-09-25 富士フイルム株式会社 イムノクロマトグラフィー
WO2021153127A1 (ja) 2020-01-31 2021-08-05 富士フイルム株式会社 免疫検査方法
CN111153992A (zh) * 2020-02-21 2020-05-15 首都医科大学附属北京胸科医院 结核分枝杆菌lam的单克隆抗体及其用途
EP4178610A4 (en) * 2020-07-07 2024-08-28 The Regents Of The University Of California METHODS FOR DETECTION OF ANTIGENS FROM DIRECT CLINICAL SAMPLES
EP4192429A4 (en) * 2020-08-05 2024-10-09 The Administrators of The Tulane Educational Fund METHOD FOR DETECTING TB IN BODY FLUID SAMPLES
JP7554275B2 (ja) 2020-09-11 2024-09-19 富士フイルム株式会社 検体液の濃縮方法、及び、検体液の検査方法
JP7590441B2 (ja) 2020-09-11 2024-11-26 富士フイルム株式会社 濃縮デバイス、検体液の濃縮方法、検体液の検査方法、及び、検査キット
CN116113826B (zh) 2020-09-11 2026-02-27 富士胶片株式会社 浓缩器件、被检体液的浓缩方法、被检体液的检查方法、及检查试剂盒
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
EP4263598A4 (en) * 2020-12-15 2025-04-09 Albert Einstein College of Medicine High-affinity mycobacterium tuberculosis capsule-specific human monoclonal antibodies
CN113480659B (zh) * 2021-06-30 2022-10-21 迪比康(上海)生物科技有限公司 人源抗结核分枝杆菌复合群lam单克隆抗体及其制备和应用
CN114984870A (zh) * 2022-03-15 2022-09-02 齐欣 一种重组蛋白质微球及其制备方法和应用
CN117247450B (zh) * 2023-10-10 2025-02-25 广州市雷德生物科技有限公司 一种lam抗体及其应用
CN118178640B (zh) * 2024-03-08 2025-11-21 中国农业大学 含有牛分枝杆菌表面多糖的佐剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309237A1 (en) * 2011-01-24 2013-11-21 Dso National Laboratories Pathogenic Mycobacteria-Derived Mannose-Capped Lipoarabinomannan Antigen Binding Proteins
CN104144944A (zh) * 2012-02-29 2014-11-12 大塚制药株式会社 抗-脂阿拉伯甘露聚糖抗体和使用该抗体对抗酸杆菌感染的免疫测定

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4636524A (en) 1984-12-06 1987-01-13 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
CA2474701C (en) 1993-11-19 2009-01-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradeable microparticles containing a biologically active agent
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US20010007660A1 (en) 1997-06-04 2001-07-12 Aharona Glatman-Freedman Methods of treating and protecting against tuberculosis using a monoclonal antibody selective for mycobacterium tuberculosis
AU1384199A (en) 1997-11-07 1999-05-31 Chiron Corporation Method for producing igf-1 sustained-release formulations
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6451346B1 (en) 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
EP1385486A4 (en) 2001-04-18 2006-05-17 Nostrum Pharmaceuticals Inc NEW COATING OF SLOW RELEASE PHARMACEUTICAL COMPOSITION
US7063725B2 (en) 2002-10-21 2006-06-20 Sdgi Holdings, Inc. Systems and techniques for restoring and maintaining intervertebral anatomy
CA2437639C (en) 2003-08-11 2016-07-05 Valera Pharmaceuticals, Inc. Long term drug delivery devices with polyurethane based polymers and their manufacture
US20050187631A1 (en) 2004-01-27 2005-08-25 Sdgi Holdings, Inc. Prosthetic device
BRPI0513596B8 (pt) * 2004-07-20 2021-07-27 Chemogen Inc método e kit para detectar uma infecção micobacteriana em uma amostra de um indivíduo de interesse por meio da detecção de antígeno micobacteriano
CN101216491B (zh) * 2008-01-08 2012-06-06 广州益善生物技术有限公司 结核分枝杆菌检测液相芯片及其制备方法
EP2242836B1 (en) * 2008-01-28 2015-05-20 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
CA2737667A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Targeted binding agents directed to cd105 and uses thereof
US8673845B2 (en) * 2009-07-29 2014-03-18 Toagosei Co., Ltd. Carrier peptide fragment and use thereof
JO3462B1 (ar) * 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
ES2970828T3 (es) 2016-02-10 2024-05-30 Univ Rutgers Nuevos anticuerpos anti-lam

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130309237A1 (en) * 2011-01-24 2013-11-21 Dso National Laboratories Pathogenic Mycobacteria-Derived Mannose-Capped Lipoarabinomannan Antigen Binding Proteins
CN104144944A (zh) * 2012-02-29 2014-11-12 大塚制药株式会社 抗-脂阿拉伯甘露聚糖抗体和使用该抗体对抗酸杆菌感染的免疫测定

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ligand Specificity of CS-35, a Monoclonal Antibody That Recognizes Mycobacterial Lipoarabinomannan: A Model System for Oligofuranoside-Protein Recognition;Rademacher等;《Journal of the American chemical society》;20070802;第129卷(第34期);第10489-10502页 *

Also Published As

Publication number Publication date
US20240307535A1 (en) 2024-09-19
US10729771B2 (en) 2020-08-04
US11707525B2 (en) 2023-07-25
EP3414573B1 (en) 2023-11-08
AU2017218415A1 (en) 2018-09-27
JP7813481B2 (ja) 2026-02-13
ZA201805990B (en) 2023-01-25
US12303562B2 (en) 2025-05-20
AU2017218415B2 (en) 2024-05-02
RU2018131622A3 (https=) 2020-04-13
JP2019506412A (ja) 2019-03-07
CN109073649A (zh) 2018-12-21
ES2970828T3 (es) 2024-05-30
CA3013904C (en) 2023-12-12
CN110092830A (zh) 2019-08-06
WO2017139153A1 (en) 2017-08-17
RU2018131622A (ru) 2020-03-10
US20200316199A1 (en) 2020-10-08
US11273220B2 (en) 2022-03-15
EP3414573A4 (en) 2019-10-30
JP2023075196A (ja) 2023-05-30
JP2021105034A (ja) 2021-07-26
ZA202209045B (en) 2023-12-20
US20220168420A1 (en) 2022-06-02
BR112018016226A2 (pt) 2019-01-02
JP2024174883A (ja) 2024-12-17
AU2024205286A1 (en) 2024-08-22
EP3414573A1 (en) 2018-12-19
JP7316685B2 (ja) 2023-07-28
US20190038747A1 (en) 2019-02-07
EP4299072A3 (en) 2024-05-01
RU2732502C2 (ru) 2020-09-18
BR112018016226A8 (pt) 2023-10-24
ZA202307912B (en) 2025-11-26
EP4299072A2 (en) 2024-01-03
CA3013904A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
CN110092830B (zh) 用于诊断和治疗结核分枝杆菌感染的抗lam和抗pim6/lam单克隆抗体
JP7747353B2 (ja) 抗コロナウイルス完全ヒト広域スペクトル中和抗体７６ｅ１及びその適用
JP7041898B2 (ja) 広域中和抗ｈｉｖ－１抗体およびその使用方法
JP2023532234A (ja) 抗ｃｄ７３抗体とその用途
CN101668776A (zh) 拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途
KR20120128688A (ko) 녹농균의 혈청형 ｉ 지질다당류에 대한 항체
KR102678252B1 (ko) 재조합 이중특이적 항체
CN112996815B (zh) 人pd-l1抗体
JP2022502508A (ja) 抗ｃｄ３０抗体薬物複合体療法を使用して末梢性ｔ細胞リンパ腫を処置する方法
CN113194996A (zh) 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
JP2018534915A5 (https=)
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
BR112018016226B1 (pt) Anticorpo antilipoarabinomanana (anti-lam) monoclonal, kit para detectar um epítopo de lam, método in vitro para diagnosticar uma infecção de tuberculose ativa em um indivíduo e método in vitro de pré-concentração de lam a partir de uma amostra biológica
CN121108356A (zh) 抗gpc3×cd3双特异性抗体及其制备方法和用途
CN121108358A (zh) 一种抗gpc3×cd3双特异性抗体及其制备方法和用途
HK40019070A (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof
HK40019070B (en) Broadly neutralizing anti-hiv-1 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant